Thursday, September 4, 2025
SCYNEXIS Announces Multiple Pr
Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistanceAdditional poste
Monday, August 25, 2025
SCYNEXIS to Participate in the
JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
Friday, August 15, 2025
SCYNEXIS Second Quarter 2025 E
SCYNEXIS ( NASDAQ:SCYX ) Second Quarter 2025 Results Key Financial Results Net loss: US$6.89m (loss narrowed by 52...
Wednesday, August 13, 2025
Scynexis: Q2 Earnings Snapshot
JERSEY CITY, N.J. (AP) — Scynexis Inc. SCYX) on Wednesday reported a loss of $6.9 million in its second quarter. The Jersey City, New Jersey-based company said it had a loss of 14 cents per share.
Wednesday, August 13, 2025
SCYNEXIS Reports Second Quarte
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six
Thursday, May 29, 2025
SCYNEXIS, Inc. (SCYX) Resumes
SCYNEXIS, Inc. (NASDAQ:SCYX) has officially restarted patient dosing in its Phase III MARIO trial for Brexafemme (ibrexafungerp) after the FDA lifted a nearly two-year clinical hold. The hold, initiat
Wednesday, May 28, 2025
Scynexis resumes dosing in Pha
The trial continuation comes amid uncertain times between Scynexis and licensing partner GSK.
Wednesday, May 28, 2025
SCYNEXIS Resumes Patient Dosin
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M miles
Thursday, May 15, 2025
Scynexis: Q1 Earnings Snapshot
JERSEY CITY, N.J. (AP) — Scynexis Inc. SCYX) on Thursday reported a loss of $5.4 million in its first quarter. The Jersey City, New Jersey-based company said it had a loss of 11 cents per share.
Thursday, May 15, 2025
SCYNEXIS Reports First Quarter
Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemm
Tuesday, April 8, 2025
SCYNEXIS to Present Preclinica
JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista
Friday, March 14, 2025
SCYNEXIS Full Year 2024 Earnin
SCYNEXIS ( NASDAQ:SCYX ) Full Year 2024 Results Key Financial Results Net loss: US$21.3m (down by 132% from US$67.0m...
Wednesday, March 12, 2025
SCYNEXIS Reports Full Year 202
The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted
Wednesday, December 18, 2024
SCYNEXIS Initiates Dosing in P
JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
Friday, November 8, 2024
SCYNEXIS Third Quarter 2024 Ea
SCYNEXIS ( NASDAQ:SCYX ) Third Quarter 2024 Results Key Financial Results Revenue: US$660.0k (down 63% from 3Q 2023...
Wednesday, November 6, 2024
Scynexis: Q3 Earnings Snapshot
JERSEY CITY, N.J. (AP) — Scynexis Inc. SCYX) on Wednesday reported a loss of $2.8 million in its third quarter. On a per-share basis, the Jersey City, New Jersey-based company said it had a loss of 6
Wednesday, November 6, 2024
SCYNEXIS Reports Third Quarter
Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYN
Wednesday, October 30, 2024
Investors in SCYNEXIS (NASDAQ:
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
Sunday, October 13, 2024
Earnings week ahead: BAC, GS,
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Thursday, October 10, 2024
SCYNEXIS to Participate in the
JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
Monday, October 7, 2024
Federated Hermes, Inc. Expands
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Thursday, October 3, 2024
SCYNEXIS to Present Preclinica
JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan